Skip to main content
Erschienen in: Journal of Neurology 7/2014

01.07.2014 | Letter to the Editors

A case of amyotrophic lateral sclerosis with intermediate ATXN-1 CAG repeat expansion in a large family with spinocerebellar ataxia type 1

verfasst von: Rossella Spataro, Vincenzo La Bella

Erschienen in: Journal of Neurology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sirs, …
Literatur
1.
Zurück zum Zitat Al-Chalabi A, Jones A, Troakes C et al (2012) The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 124:339–352CrossRefPubMed Al-Chalabi A, Jones A, Troakes C et al (2012) The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 124:339–352CrossRefPubMed
2.
Zurück zum Zitat Elden AC, Kim H-J, Hart MP et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increate risk for ALS. Nature 466:1069–1075PubMedCentralCrossRefPubMed Elden AC, Kim H-J, Hart MP et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increate risk for ALS. Nature 466:1069–1075PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Conforti FL, Spataro R, Sproviero W et al (2012) Ataxin-1 and ataxin-2 intermediate-length poly-Q expansions in amyotrophic lateral sclerosis. Neurology 79:2315–2320CrossRefPubMed Conforti FL, Spataro R, Sproviero W et al (2012) Ataxin-1 and ataxin-2 intermediate-length poly-Q expansions in amyotrophic lateral sclerosis. Neurology 79:2315–2320CrossRefPubMed
4.
Zurück zum Zitat Lee T, Li Y-R, Chesi A et al (2011) Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 76:2062–2065PubMedCentralCrossRefPubMed Lee T, Li Y-R, Chesi A et al (2011) Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 76:2062–2065PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Magana JJ, Velasquez-Perez L, Cisneros B (2013) Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. Mol Neurobiol 47:90–104CrossRefPubMed Magana JJ, Velasquez-Perez L, Cisneros B (2013) Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. Mol Neurobiol 47:90–104CrossRefPubMed
6.
Zurück zum Zitat Goldfarb LG, Vasconcelos O, Platonov FA et al (1996) Unstable triplet repeat and phenotypic variability of spinocerebellar ataxia type 1. Ann Neurol 39:500–506CrossRefPubMed Goldfarb LG, Vasconcelos O, Platonov FA et al (1996) Unstable triplet repeat and phenotypic variability of spinocerebellar ataxia type 1. Ann Neurol 39:500–506CrossRefPubMed
7.
Zurück zum Zitat Fukazawa SH, Yanagihara T, Yanagihara T et al (1996) Clinical features and natural history of spinocerebellar ataxia type I. Acta Neurol Scand 93:64–71PubMed Fukazawa SH, Yanagihara T, Yanagihara T et al (1996) Clinical features and natural history of spinocerebellar ataxia type I. Acta Neurol Scand 93:64–71PubMed
8.
Zurück zum Zitat Nanetti L, Fancellu R, Tomasello C et al (2009) Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. J Neurol 256:1926–1928CrossRefPubMed Nanetti L, Fancellu R, Tomasello C et al (2009) Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. J Neurol 256:1926–1928CrossRefPubMed
9.
Zurück zum Zitat Tazen S, Figueroa K, Kwan JY et al (2013) Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2. JAMA Neurol 70:1302–1304PubMedCentralPubMed Tazen S, Figueroa K, Kwan JY et al (2013) Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2. JAMA Neurol 70:1302–1304PubMedCentralPubMed
10.
Zurück zum Zitat Kimura F, Fujimura C, Ishida S et al (2006) Progression rate of ALSFRS-R at the time of diagnosis predicts survival time in ALS. Neurology 66:265–267CrossRefPubMed Kimura F, Fujimura C, Ishida S et al (2006) Progression rate of ALSFRS-R at the time of diagnosis predicts survival time in ALS. Neurology 66:265–267CrossRefPubMed
11.
Zurück zum Zitat Okuda T, Hattori H, Takeuchi S et al (2003) PQBP-1 transgenic mice show a late-onset motor neuron disease-like phenotype. Hum Mol Genet 12:711–725CrossRefPubMed Okuda T, Hattori H, Takeuchi S et al (2003) PQBP-1 transgenic mice show a late-onset motor neuron disease-like phenotype. Hum Mol Genet 12:711–725CrossRefPubMed
12.
Zurück zum Zitat Farg MA, Soo KY, Warraich ST et al (2013) Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum Mol Genet 22:717–728CrossRefPubMed Farg MA, Soo KY, Warraich ST et al (2013) Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum Mol Genet 22:717–728CrossRefPubMed
13.
Zurück zum Zitat Nihei Y, Ito D, Suzuki N (2012) Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS). J Biol Chem 287:41310–41323PubMedCentralCrossRefPubMed Nihei Y, Ito D, Suzuki N (2012) Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS). J Biol Chem 287:41310–41323PubMedCentralCrossRefPubMed
Metadaten
Titel
A case of amyotrophic lateral sclerosis with intermediate ATXN-1 CAG repeat expansion in a large family with spinocerebellar ataxia type 1
verfasst von
Rossella Spataro
Vincenzo La Bella
Publikationsdatum
01.07.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 7/2014
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7400-1

Weitere Artikel der Ausgabe 7/2014

Journal of Neurology 7/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.